Literature DB >> 26618254

Regulatory T lymphocytes in myocardial infarction: A promising new therapeutic target.

Ya-ping Wang1, Yao Xie2, Hong Ma3, Sheng-an Su1, Yi-dong Wang1, Jian-an Wang1, Mei-xiang Xiang4.   

Abstract

Myocardial infarction (MI) is one of the leading causes of death especially in developed countries. Although the advent of early myocardial reperfusion therapy contributes to decreasing the mortality of patients with MI, cardiac ischemia-reperfusion injury and adverse remodeling during the repair process still remain the major factors impairing cardiac function and resulting in unsatisfactory prognosis. Excessive inflammation and immune responses play a crucial role during the whole process of MI. Regulatory T lymphocytes, characterized by immunosuppressive capacity, are associated with many immune-related diseases. Recent studies have proven a protective role of regulatory T cells in MI, which is mainly achieved by modulating inflammation and immune responses. In this review, we will summarize current knowledge of regulatory T lymphocytes, and highlight their roles in the onset of MI, ischemia-reperfusion injury, as well as post-infarct cardiac healing and remodeling.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Ischemia-reperfusion injury; Myocardial infarction; Plaque instability; Regulatory T lymphocyte; Ventricular remodeling

Mesh:

Year:  2015        PMID: 26618254     DOI: 10.1016/j.ijcard.2015.11.078

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  8 in total

1.  Myocardial infarction triggers cardioprotective antigen-specific T helper cell responses.

Authors:  Max Rieckmann; Murilo Delgobo; Chiara Gaal; Lotte Büchner; Philipp Steinau; Dan Reshef; Cristina Gil-Cruz; Ellis N Ter Horst; Malte Kircher; Theresa Reiter; Katrin G Heinze; Hans Wm Niessen; Paul Aj Krijnen; Anja M van der Laan; Jan J Piek; Charlotte Koch; Hans-Jürgen Wester; Constantin Lapa; Wolfgang R Bauer; Burkhard Ludewig; Nir Friedman; Stefan Frantz; Ulrich Hofmann; Gustavo Campos Ramos
Journal:  J Clin Invest       Date:  2019-08-13       Impact factor: 14.808

Review 2.  Role of the immune system in cardiac tissue damage and repair following myocardial infarction.

Authors:  Arman Saparov; Vyacheslav Ogay; Talgat Nurgozhin; William C W Chen; Nurlan Mansurov; Assel Issabekova; Jamilya Zhakupova
Journal:  Inflamm Res       Date:  2017-06-09       Impact factor: 4.575

Review 3.  Galectin-1 as an Emerging Mediator of Cardiovascular Inflammation: Mechanisms and Therapeutic Opportunities.

Authors:  Ignacio M Seropian; Germán E González; Sebastián M Maller; Daniel H Berrocal; Antonio Abbate; Gabriel A Rabinovich
Journal:  Mediators Inflamm       Date:  2018-11-05       Impact factor: 4.711

Review 4.  Lymphocytic subsets play distinct roles in heart diseases.

Authors:  Jing Wang; Yi Duan; Joost Pg Sluijter; Junjie Xiao
Journal:  Theranostics       Date:  2019-05-31       Impact factor: 11.556

Review 5.  Healing the Broken Heart; The Immunomodulatory Effects of Stem Cell Therapy.

Authors:  Marcus J Wagner; Mohsin Khan; Sadia Mohsin
Journal:  Front Immunol       Date:  2020-04-09       Impact factor: 7.561

6.  Platelet-to-Lymphocyte Ratio at Admission as a Predictor of In-Hospital and Long-Term Outcomes in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.

Authors:  Herick Alvenus Willim; Joan Carmen Harianto; Harie Cipta
Journal:  Cardiol Res       Date:  2021-02-23

Review 7.  Inflammation following acute myocardial infarction: Multiple players, dynamic roles, and novel therapeutic opportunities.

Authors:  Sang-Bing Ong; Sauri Hernández-Reséndiz; Gustavo E Crespo-Avilan; Regina T Mukhametshina; Xiu-Yi Kwek; Hector A Cabrera-Fuentes; Derek J Hausenloy
Journal:  Pharmacol Ther       Date:  2018-01-09       Impact factor: 12.310

Review 8.  The Role of Immune Cells in Cardiac Remodeling After Myocardial Infarction.

Authors:  Youming Zhang; Wei Wen; Haibo Liu
Journal:  J Cardiovasc Pharmacol       Date:  2020-10       Impact factor: 3.271

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.